Last reviewed · How we verify

NCT06072235

Facemasks and Chronic Pain Patients With Hearing Loss

Completed Last updated 27 January 2025
What this trial tests

trial testing Verbal communication in Hearing Loss in 500 participants. Completed in 11 December 2024.

Timeline
8 January 2018
Primary endpoint
11 December 2024
11 December 2024

Quick facts

Lead sponsorSalem Anaesthesia Pain Clinic
StatusCompleted
Study typeOBSERVATIONAL
Enrollment500
Start date8 January 2018
Primary completion11 December 2024
Estimated completion11 December 2024
Sites1 location across Canada

Drugs / interventions tested

Conditions studied

Sponsor

Salem Anaesthesia Pain Clinic

Who can join

Adults 20 to 99, any sex, with Hearing Loss or Chronic Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Facemasks may impede communication. Impaired communication may worsen healthcare outcomes. This study explores the problem of hearing impairment in chronic pain patients, and the impact of facemasks on healthcare outcomes in chronic pain patients. Data collection includes patient's age, anxiety score, depression score, numeric pain score, and effects of facemasks on treatment outcomes. Pain is measured using numeric pain rating scale. Depression is measured using the Patient Health Questionnaire (PHQ-9) scale. Anxiety is measured using the General Anxiety Disorder (GAD-7) scale.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hearing Loss

Currently open trials in the same condition.

Other Salem Anaesthesia Pain Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06072235.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing